Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-01-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于归还募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the return of raised funds temporarily used to supplement working capital. It details the use and return of funds raised from a 2015 non-public stock issuance. The document is short (832 characters) and focuses on the status and compliance of the use of raised funds rather than presenting financial statements or detailed financial data. It is an update on capital usage and financing activities, specifically about the return of funds raised. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-01-15 Chinese
关于获得国家科学技术进步奖的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. about receiving a National Science and Technology Progress Award. It contains no financial data, no mention of financial results, no regulatory filings, no meeting materials, or voting results. It is a general corporate announcement about an award received, which does not fit into any specific financial report category. Given the content and length (623 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other categories.
2018-01-10 Chinese
关于“昆药集团股份有限公司2015年公司债券”2018年度第一次债券持有人会议的决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the resolution of a bondholders' meeting for Kunming Pharmaceutical Group Co., Ltd. It details the meeting's convocation, attendance, agenda, and the fact that no valid resolution was formed due to insufficient voting rights represented. It also includes legal opinions and subsequent procedural explanations. The document is short (1399 characters) and serves as a formal announcement of the meeting outcome rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-01-05 Chinese
北京德恒（昆明）律师事务所关于公司2015年公司债券2018年度第一次债券持有人会议的法律意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the convening and holding of a bondholders' meeting for Kunming Pharmaceutical Group Co., Ltd.'s 2015 corporate bonds in 2018. It discusses the procedures for the bondholders' meeting, qualifications of attendees, and the outcome that the meeting did not reach a quorum and thus no valid resolution was formed. The document is not a financial report, earnings release, or management discussion. It is a legal proceeding related to bondholder meetings and their compliance with laws and regulations. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 3833 characters, which is sufficient for a detailed legal opinion rather than a brief announcement or certification. Hence, the classification is LTR with high confidence.
2018-01-05 Chinese
关于注销部分已回购股票减少公司注册资本暨通知债权人公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the cancellation of part of the repurchased shares and the consequent reduction in registered capital. It includes details about the share repurchase, the board and shareholder approvals, and a notification to creditors about their rights to claim debts within a specified period. The document is a formal public notice related to corporate actions affecting share capital and creditor notification, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the share cancellation and creditor notification. This fits the category of Share Issue/Capital Change (SHA), as it concerns changes in the company's capital structure due to share cancellation after repurchase.
2018-01-03 Chinese
关于公司原董事袁平东先生减持股份计划的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding a former director's plan to reduce (sell) his shares in the company. It details the number of shares held, the planned reduction amount, timing, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussion of financial results. The content focuses on insider share transactions by a company director. Therefore, this fits the category of Director's Dealing (DIRS). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2018-01-02 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.